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Abstract
The presence of anti-a-fodrin autoantibodies has been reported 
to be a highly specific and sensitive test for the diagnosis of 
Sjögren's syndrome (SjS). W e looked (in Nijmegen) for anti-a- 
fodrin, anti-Ro60, and anti-La autoantibodies in a cohort of 
51 patients with rheumatic diseases (primary SjS [21], 
secondary SjS [6], rheumatoid arthritis [RA] [12], systemic 
lupus erythematosus [SLE] [6], and scleroderma [6]) and in 
28 healthy subjects, using ELISA, immunoblotting, and 
immunoprecipitation. The same samples were analyzed with an 
alternative anti-a-fodrin ELISA in Hanover. The Nijmegen ELISA 
of the sera from primary SjS showed sensitivities of 43%  and 
48%  for IgA- and IgG-type anti-a-fodrin antibodies, respectively. 
The Hanover ELISA showed sensitivities of 38%  and 10% for 
IgA- and IgG-type anti-a-fodrin antibodies, respectively. The
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ELISAs for a-fodrin showed six (Nijmegen) and four (Hanover) 
anti-a-fodrin-positive RA sera. IgA and IgG anti-fodrin antibodies 
were also present in four patients with secondary SjS. The 
sensitivities of Ro60 and La-antibodies in the Nijmegen ELISA 
were 67%  and 62%, respectively. Unlike anti-a-fodrin 
antibodies, all anti-Ro60 and anti-La positive sera could be 
confirmed by immunoblotting or RNA immunoprecipitation. 
Thus, anti-Ro and anti-La autoantibodies were more sensitive 
than anti-a-fodrin autoantibodies in ELISA and were more 
frequently confirmed by other techniques. Anti-La antibodies 
appear to be more disease-specific than anti-a-fodrin 
antibodies, which are also found in RA sera. Therefore, the 
measurement of anti-a-fodrin autoantibodies does not add 
much to the diagnosis of Sjögren's syndrome.
Introduction
Sjogren's syndrome (SjS) is a chronic autoimmune 
exocrinopathy of unknown origin. Therefore the diagnosis 
of SjS, in the absence of a gold standard, is based on cri­
teria containing a number of subjective and objective 
signs and symptoms. In the past three decades, several 
sets of criteria have been introduced [1-4], in which there 
has been a shift from emphasis on subjective symptoms, 
such as complaints of dry eyes or dry mouth, towards 
objective findings. Recently, a widely supported consen­
sus was established to merge the most frequently used 
European (European Study Group [ESG]) and US (San 
Diego, San Francisco) classification criteria sets into one
US/European set [5]. The authors of all three major classi­
fication criteria sets previously used took part in this con­
sensus group. In the US/European classification criteria, 
more weight is put on the presence of anti-Ro and anti-La 
antibodies in the serum, and on the lymphocytic focus 
score (LFS) of the sublabial glands, both being objective 
signs. The cutoff point of a positive LFS was set at > 1.0, 
which ended a long-lasting debate about whether an LFS 
of > 1.0 (ESG criteria), >1.0  (San Francisco criteria), or
> 2.0 (San Diego criteria) was most applicable for the 
diagnosis of SjS. This agreement ultimately will produce 
uniform intercontinental disease prevalence data. 
However, the disease specificity of particularly anti-La anti-
ELISA =  enzyme-linked immunosorbent assay; ESG =  European Study Group; FCS =  fetal calf serum; LFS =  lymphocytic focus score; NHS =  
normal healthy subjects; pGEX-4T2 =  a  fodrin cDNA in a GST expression vector; RA =  rheumatoid arthritis; SjS =  Sjogren's syndrome; SLE =  
systemic lupus erythematosus; SS-A =  anti-Ro60 (antibodies); SS-B =  Anti-La (antibodies); SSc =  systemic sclerosis. R33
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bodies is limited (besides being found in SjS, they are also 
found in systemic lupus erythematosus [SLE]), and the 
sensitivities of anti-Ro and anti-La antibodies range only 
from 60-75%  and 30-50% , respectively [6-9]. There­
fore, the search for more sensitive and specific diagnostic 
markers needs to be continued.
Haneji and co-workers [10] suggested a 120-kDa cleav­
age product of a-fodrin (a cytoskeletal protein) as a candi­
date autoantigen in SjS. They reported that the presence 
of anti-a-fodrin antibodies was very specific for the diag­
nosis of S jS and claimed a very high sensitivity (96%). In 
another report of the same group, however, these antibod­
ies were also found in some sera of patients with SLE
[11]. Their results suggested that anti-a-fodrin antibodies 
might replace anti-Ro and anti-La antibodies, as a more 
objective serological marker to improve the diagnostic 
value of classification criteria. This suggestion was sup­
ported by W itte and co-workers, who developed an ELISA 
for the detection of anti-a-fodrin antibodies and showed 
that IgA antibodies against a-fodrin provided an even 
higher sensitivity than IgG antibodies [12].
The objective of this study was to measure the presence of 
anti-a-fodrin antibodies in the sera of a cohort of patients 
with well-defined SjS at the Department of Rheumatology 
of the University Medical Center St Radboud, Nijmegen, 
The Netherlands. A second objective was to evaluate 
whether positive anti-fodrin ELISA results could be con­
firmed by at least one alternative biochemical technique 
such as immunoblotting or protein immunoprecipitation.
Materials and methods
Patients and measurement techniques
The sera of 21 patients (18 women and 3 men, aged 
2 7 -7 6  years, median 55 years) with well-defined primary 
SjS according to the US/European criteria [5] were tested 
along with the sera of 6 patients with secondary SjS (all 
women, aged 4 1 -5 5  years), 28 normal healthy subjects 
(NHS) (19 women and 9 men, aged 24-61 years, median 
43 years), 12 patients with rheumatoid arthritis (RA) and 
without signs of secondary SjS (8 women and 4 men, 
aged 3 2 -7 2  years, median 47 years), 6 with SLE (all 
women, aged 3 3 -5 6  years), and 6 with systemic sclerosis 
(SSc) (3 women and 3 men, aged 3 6 -4 9  years).
All the patients tested were white. To fulfill the US/Euro­
pean classification criteria, all SjS patients had to have a 
biopsy of the sublabial salivary glands showing an LFS
> 1.0. Furthermore, immunohistochemical examination had 
to show a percentage IgA-containing plasma cells of less 
than 70, a feature that is also strongly associated with SjS 
and slightly more disease specific than the LFS [13,14]. 
The comorbidity of the six patients with secondary SjS is 
shown in Table 1. Secondary SjS was accompanied by 
R34 SLE in four patients, by systemic sclerosis in another
patient, and by dermatomyositis in yet another. None of 
the SjS patients was receiving an immunosuppressant.
The presence of anti-a-fodrin antibodies in the sera was 
measured with three different biochemical techniques: 
ELISA, immunoblotting with recombinant fodrin, and 
immunoprecipitation of radiolabeled fodrin. Furthermore, a 
blinded set of our serum samples was analyzed by W itte 
and co-workers using the anti-a-fodrin ELISA developed in 
Hanover, Germany (referred to as Hanover ELISA) [12].
Expression of the 120-kDa a-fodrin fragment
For the expression of the antigenic fodrin fragment, we 
used the a-fodrin cDNA in a GST expression vector 
(pGEX-4T2), which was kindly supplied by Dr Y Hayashi 
(Tokushima University School of Dentistry, Tokushima, 
Japan). The cDNA was expressed in BL21 (DE3) cells, 
and the protein was affinity-purified using glutathione 
Sepharose beads (Amersham Pharmacia Biotech).
ELISA
The presence of IgA, IgG, and IgM anti-a-fodrin antibodies 
in sera in 100-fold dilution was assessed by ELISA. Plates 
were coated with purified a-fodrin-GST as antigen, and 
bound antibody was detected essentially as described by 
Schellekens and colleagues [15], using rabbit peroxidase- 
conjugated anti-human immunoglobulins (anti-IgG, anti- 
IgA, or anti-IgM, DAKO, Glostrup, Denmark).
Sera were considered positive when the optical density at 
X 450 nm values after correction for background value 
exceeded the mean + 2 s d  of that of a pool of sera from 
NHS. All ELISAs were performed in duplicate. To check 
for possible false-positive results because of the presence 
of the GST moiety in the a-fodrin-GST product that was 
used as the antigen, the ELISA was also performed in the 
presence of a 10-fold excess of purified carrier GST.
Anti-La (SS-B) and anti-Ro60 (SS-A) autoantibodies were 
measured by ELISA, using recombinant La and Ro60 pro­
teins. All sera were also analyzed by immunoblotting and 
RNA immunoprecipitation to confirm the presence of anti­
Ro and anti-La antibodies, as previously described [16].
Immunoblotting
To confirm the ELISA results, reactivity of sera against 
recombinant fodrin-G ST was evaluated by western 
blotting essentially as described elsewhere [17]. The 
human sera were diluted 5000-fold with blocking buffer. A 
second antibody directed against total human 
immunoglobulin was used (DAKO, Glostrup, Denmark). In 
a similar type of experiment, immunoblots containing 
extracts from apoptotic Jurkat cells, prepared according to 
the method of Zampieri and colleagues [18] and believed 
to contain the native and possibly modified apoptotic a- 
fodrin fragment of 120 kDa described by Haneji and
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Table 1
Autoantibodies in Nijmegen sera from a cohort of patients with Sjogren’s syndrome
IgAa IgGb
Pt no. Nijmegen Hanoverc Nijmegen Hanoverc IBd IPe Ro60f Laa LFSh Comorbidity
Primary Sjögren's syndrome 
1 + + + + +
2 -  - - - - - - + +
3 + - - - - - - - +
4 + + + - - - + - +
5 + + + - + + + + +
6 + - - - - + + + +
7 + - - - - - - - +
8 -  + - - - - - - +
9 -  + + - - - + - +
10 + + + - - + + + +
11 -  - - - - - + + +
12 -  - - - + - + - +
13 -  - + - - - + + +
14 -  - - - + + + + +
15 -  - + - - - + + +
16 -  - - - + - - - +
17 -  - + - - - + + +
18 + + - - - - - + +
19 -  - - - + - - - +
20 + + + + - - + + +
21 -  - + + - - + + +
Secondary Sjögren's syndrome 
22 + + + + + + + + SLE
23 + + + + + + + + + SLE
24 -  - - - - - + - + SLE
25 + + + + + + - - + SLE
26 + + + - + - + + + SSc
27 -  - + - - - + - + DM
aIgA, ELISA measuring presence of IgA antibodies directed against a-fodrin; bIgG, ELISA measuring presence of IgG antibodies directed against 
a-fodrin; cfindings in Hanover for the sera originally tested in Nijmegen; dIB, immunoblotting results (a-fodrin); eIP, protein immunoprecipitation 
results (a-fodrin); fRo60, ELISA measuring presence of antibodies directed against Ro60-antigen; sLa, ELISA measuring presence of antibodies 
directed against La-antigen; hLFS, lymphocytic focus score > 1.0 in sublabial minor salivary glands biopsy. DM, dermatomyositis; Pt, patient;
SSc, systemic sclerosis; SLE, systemic lupus erythematosus.
coworkers, were used. Visualization was performed by 
chemiluminescence.
Immunoprecipitation of radiolabeled a-fodrin
For labeling of cellular proteins, HeLa cells were incu­
bated in medium without methionine and supplied with
2% dialyzed fetal calf serum (FCS). After 1 hour, 10 |j,Ci 
[35S]methionine per ml was added and the concentration 
of dialyzed FCS was raised to 5%. After an additional 
4 hours, 1 volume of complete medium containing 10% 
FCS (undialyzed) was added and incubation was contin­
ued for 16 hours at 37°C. The cells were collected by R35
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centrifugation, washed, and homogenized in lysis buffer 
(50 mM Tris/HCl, pH7.5, 0.5% NP40, 100mM KCl, 1 mM 
dithioerythritol, 1 mM EDTA) containing a mixture of pro­
tease inhibitors. IgG antibodies from sera to be analyzed 
(SjS and controls) were coupled to protein A-agarose 
beads (Biozym, Landgraaf, The Netherlands) and immuno- 
precipitations were carried out as described by Raijmak- 
ers and colleagues [17].
Hanover ELISA confirmation
Another way to confirm our ELISA results was to compare 
our data with those obtained with the Hanover ELISA 
developed by W itte and colleagues [12]. A blinded set of 
serum samples was therefore analyzed in Hanover.
Results
Analysis for anti-a-fodrin, anti-La, and anti-Ro60 by ELISA
Using the purified a-fodrin-GST protein encoded by the 
cDNA construct obtained from Dr Hayashi, we developed 
an ELISA (hereafter referred to as the Nijmegen ELISA) 
that was used for the analysis of SjS and control sera. The 
Nijmegen IgA ELISA test appeared to be reasonably spe­
cific. Only one serum positive for anti-a-fodrin was found 
among the 12 RA sera. In the 28 NHS sera and 12 sera 
from SLE and SSc patients, no IgA anti-a-fodrin antibod­
ies were detected. In the IgG ELISA, however, six RA sera 
were positive; the other control sera (NHS, SLE, and SSc) 
were negative.
Of the 21 sera from primary SjS, 10 were found positive in 
the IgG ELISA, indicating a disease sensitivity of IgG anti­
bodies against a-fodrin of 48%. Nine (43%) of the 
21 primary SjS sera were found to contain IgA antibodies 
against a-fodrin (Table 1) and 3 (14%) of the 21 con­
tained IgM antibodies against a-fodrin (not shown). Five of 
the nine primary SjS sera with IgA antibodies to fodrin also 
contained IgG antibodies directed against this antigen.
To be sure that the antibodies measured were directed 
against the fodrin part of the fodrin-GST fusion protein, 
the ELISAs were also carried out in the presence of a 
10-fold excess of purified GST protein. Essentially the 
same results were obtained.
The same sera (blinded) were also analyzed in Hanover by 
W itte and coworkers using their a-fodrin ELISA [12]. The 
Hanover results showed a disease sensitivity of 38% for 
IgA and of 10% for IgG antibodies against a-fodrin. Six of
8 sera from primary SjS that were positive in the Hanover 
IgA ELISA were also positive in the Nijmegen ELISA, so 
that 6 of 21 sera from primary SjS (29%) conclusively 
seemed to contain IgA antibodies directed against 
a-fodrin. While the data for IgA-positive sera from both 
ELISAs were quite congruent, data for IgG-positive sera 
showed clear discrepancies (Table 1). W e do not know 
R36 why.
W e also looked for the classic anti-La and anti-Ro60 
autoantibodies in the 21 sera from primary SjS. Fourteen 
sera contained anti-Ro60 (SS-A) antibodies (sensitivity 
67%) and 13 sera contained anti-La (SS-B) antibodies 
(sensitivity 62%). These activities were confirmed by at 
least one other technique (immunoblotting and/or RNA 
precipitation). Anti-La and anti-Ro activities were absent in 
all control sera that were included in this study (data not 
shown). There was also considerable overlap between the 
presence of anti-a-fodrin and anti-Ro60 or anti-La. Of the
9 IgA-positive sera from primary SjS, 6 contained anti- 
Ro60 and 5 contained anti-La, while of the 10IgG-posi- 
tive sera, all contained anti-Ro60 also and 7 contained 
anti-La antibodies (Table 1).
Four of six sera from patients with secondary SjS con­
tained IgA and IgG antibodies against a-fodrin. Three of 
these sera also contained anti-Ro and anti-La antibodies 
(Table 1). From these results we conclude that anti- 
a-fodrin antibodies are present in SjS sera and that the 
majority of these antibodies are of the IgG and IgA class, 
but that their frequency in SjS sera is not higher than that 
of the classic autoantibodies directed against the Ro60 
and La antigens.
Analysis for anti-a-fodrin antibodies by western 
blotting and immunoprecipitation
W e also analyzed the sera for anti-a-fodrin antibodies by 
two other techniques (immunoblotting and protein 
immunoprecipitation) to confirm the ELISA results. In 
general, these two techniques appeared to be less suited 
for this purpose. The size of the antigen (250 kDa) and its 
limited presence in cultured cells precluded both efficient 
blotting and efficient labeling by [35S]methionine. There 
were also some background problems that in some cases 
made it difficult to distinguish between positive and nega­
tive sera. W e therefore decided to count only those sera 
that were clearly positive.
Of the sera from primary SjS, five appeared to be positive 
in immunoblotting and four precipitated a protein with the 
expected molecular weight of fodrin. Two of those that 
immunoprecipitated fodrin were also positive on 
immunoblot, and three also contained IgA and/or IgG anti­
bodies to a-fodrin as measured by ELISA (Table 1).
The presence of anti-fodrin antibodies in four sera of 
patients with secondary SjS was confirmed by 
immunoblotting (four of four) and by immunoprecipitation 
(three of four) (Table 1).
In our hands, the use of apoptotic extracts (to increase the 
amount of antigenic fodrin cleavage product) did not 
improve the suitability of these techniques for the detec­
tion of anti-a-fodrin antibodies (data not shown).
A va ila b le  o n lin e  http://arthritis-research.cOm/content/6/1/R33
Discussion
The presence of anti-Ro and anti-La autoantibodies has 
been part of the classification criteria for Sjögren's syn­
drome (SjS), including the recently established US/Euro­
pean consensus group criteria, in which they play a more 
significant role than before [5]. According to these classifi­
cation criteria, the presence of either anti-Ro or anti-La 
autoantibodies or a positive salivary gland biopsy (LFS
> 1.0) is mandatory for the classification of SjS. The 
disease sensitivities of anti-Ro and anti-La autoantibodies 
have been reported to be 60 -75%  and 30-50% , respec­
tively [6-9], while the specificity of particularly anti-La 
autoantibodies is generally considered to be reasonably 
high. Anti-La autoantibodies are mostly found in SjS and 
SLE patients, and rarely in other diseases or normal 
healthy subjects. Nevertheless, there is certainly a need 
for an SjS-specific autoantibody showing a better disease 
sensitivity and specificity profile.
Haneji and colleagues suggested the presence of anti-a- 
fodrin autoantibodies as a highly specific diagnostic 
marker for SjS. In their initial paper, they reported that 
96% of sera from primary SjS reacted with a-fodrin [10]. 
In follow-up studies, however, they also noticed the pres­
ence of these autoantibodies in SLE patients [11]. W itte 
and collaborators showed much lower disease sensitivi­
ties, of 64% and 47% in primary and secondary Sjögren's 
syndrome, respectively, when focusing on IgA antibodies 
against a-fodrin rather than IgG antibodies [12]. Their 
data suggest a sensitivity similar to that of anti-Ro antibod­
ies. However, W itte and co-workers also noticed two posi­
tive sera in RA patients without symptoms of SjS, and one 
positive serum in the SLE group. These results indicate 
that the disease specificity of anti-a-fodrin antibodies 
might also be lower than reported previously.
In our cohort of patients with primary SjS, the ELISA tests 
of 21 sera showed sensitivities of 43% and 48% for IgA 
antibodies and IgG antibodies against a-fodrin, respec­
tively; these are comparable to the percentages reported 
by W itte and co-workers. In the blinded set of control sera 
analyzed in Nijmegen and Hanover, no positive tests were 
found in the NHS, SLE, or SSc sera, suggesting that the 
ELISA tests in both laboratories are specific. However, of 
the 12 RA sera tested in Hanover, four gave positive 
results in the IgA ELISA, including the one that was also 
positive in Nijmegen. Of the six RA sera that were positive 
in the IgG ELISA in Nijmegen, three were also positive in 
the IgG ELISA of Hanover. These data, together with the 
previously reported positive RA sera by W itte and co­
workers, indicate that the presence of anti-fodrin antibod­
ies in a subset of RA patients cannot be ruled out. 
Although in this study disease specificity was not evalu­
ated against a large variety of control sera from other dis­
eases, these results suggest that the disease specificity of 
anti-fodrin antibodies is unlikely to exceed that of anti-La
antibodies, which are almost exclusively found in either 
SjS or SLE sera. Elucidating the precise disease speci­
ficity of anti-fodrin antibodies, which was not the aim of 
this study, can be done when larger cohorts of patients 
are available.
It should also be noted that anti-Ro- and anti-La- antibod­
ies themselves are part of the US/European classification 
criteria, which may bias comparison between the classical 
versus anti-fodrin antibodies by means of these criteria. To 
overcome this potential problem, the presence of classical 
versus anti-fodrin antibodies in SjS patients can also be 
related to findings of the single next most important objec­
tive tool: the salivary gland biopsy. Since in our study all 
patients that were defined as having SjS at least had to 
have a positive LFS, the conclusions remain the same.
This study also showed that there are discrepancies 
between the two anti-fodrin ELISA systems. An explana­
tion of this imperfect reproducibility between the two labo­
ratories might be that the titers of anti-a-fodrin antibodies 
in patient sera were generally low in both ELISA systems. 
Consequently, small changes in the protocol would 
become important for the outcome. These observations 
underline once more the importance of an easy-to-perform 
alternative biochemical technique to confirm ELISA data 
[19].
Conclusion
Based on the difficulties encountered in this study to 
confirm the presence of anti-fodrin antibodies via alterna­
tive techniques, it is questionable whether anti-fodrin anti­
bodies should replace the classic anti-Ro and anti-La 
antibodies in the classification criteria of SjS.
All anti-Ro and anti-La activities in our sera detected by 
ELISA could be confirmed using alternative biochemical 
techniques. Besides that, the observed sensitivity of these 
classic autoantibodies is higher than that of anti-a-fodrin 
antibodies, regardless of the anti-fodrin ELISA system 
(Hanover versus Nijmegen ELISA) that was used. In addi­
tion, a considerable overlap between the presence of anti- 
Ro60/anti-La antibodies and anti-a fodrin antibodies was 
observed. A potential contributing role for the measure­
ment of anti-fodrin antibodies to detect SjS patients who 
are negative for anti-Ro60 and anti-La autoantibodies 
therefore appears unlikely. Anti-fodrin antibodies may still 
have some diagnostic value assuming that their incidence 
in SLE sera is low, which has yet to be confirmed in addi­
tional studies.
Based on the lower frequency, as compared to anti-Ro 
and anti-La, and the questionable specificity, we conclude 
that testing for anti-a-fodrin antibodies does not have 
much additional value for the diagnosis of Sjogren's syn­
drome. R37
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